Inhibition of Raf Kinase in the Treatment of Acute Myeloid Leukemia

E-ISSN： 1873-4286|8|25|2243-2248

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.8, Iss.25, 2002-11, pp. : 2243-2248

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of quizartinib in the treatment of acute myeloid leukemia

By Ostronoff Fabiana Estey Elihu

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 12, 2013-12 ,pp. : 1659-1669

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibodies for the Treatment of Acute Myeloid Leukemia

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 343-369

Bentham Science Publishers

Access to resources Recommend Favorite

Perifosine – a new option in treatment of acute myeloid leukemia?

By Krawczyk Janusz Keane Niamh Swords Ronan O'Dwyer Michael Freeman Ciara L Giles Francis J

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1315-1327

Informa Healthcare

Access to resources Recommend Favorite

Lenalidomide as a novel treatment of acute myeloid leukemia

By Chen Yiming Borthakur Gautam

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 3, 2013-03 ,pp. : 389-397

Informa Healthcare

Access to resources Recommend Favorite

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By Alvarado Yesid Kantarjian Hagop M. Luthra Rajyalakshmi Ravandi Farhad Borthakur Gautam Garcia-Manero Guillermo Konopleva Marina Estrov Zeev Andreeff Michael Cortes Jorge E.

Cancer, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

Blackwell Publishing

Access to resources Recommend Favorite